Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Spira

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Gastrointestinal Endoscopy|November 1, 1975
Fiberoptic-coupled argon laser in the control of experimentally produced gastric bleedingA M Waitman, I Spira, C P Chryssanthou, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1990
Yeast structural gene (APN1) for the major apurinic endonuclease: homology to Escherichia coli endonuclease IVS C Popoff, A I Spira, A W Johnson, et al.
Anti-Cancer Drugs|September 11, 2019
A review of canakinumab and its therapeutic potential for non-small cell lung cancerKara M Schenk, Joshua E Reuss, Karin Choquette, et al.
Clinical Lung Cancer|December 12, 2025
Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLCAlexander I Spira, David Berz, Robert M Jotte, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2025
A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups"Matthew G Krebs, Byoung Chul Cho, Priya Kim, et al.
Advances in Therapy|May 29, 2025
Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended TherapyAlexander I Spira, Tao Ran, Iris Lin, et al.
ESMO Open|September 6, 2025
Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolismS A Piha-Paul, A W Tolcher, A L Vandross, et al.
Medical Oncology (Northwood, London, England)|April 27, 2017
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancerBryan Oronsky, Carolyn M Ray, Alexander I Spira, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2009
Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancerCraig Reynolds, David Barrera, Robert Jotte, et al.
The Journal of Experimental Medicine|January 1, 1996
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaquesA I Spira, P A Marx, B K Patterson, et al.
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Gastrointestinal Endoscopy|November 1, 1975
Fiberoptic-coupled argon laser in the control of experimentally produced gastric bleedingA M Waitman, I Spira, C P Chryssanthou, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1990
Yeast structural gene (APN1) for the major apurinic endonuclease: homology to Escherichia coli endonuclease IVS C Popoff, A I Spira, A W Johnson, et al.
Anti-Cancer Drugs|September 11, 2019
A review of canakinumab and its therapeutic potential for non-small cell lung cancerKara M Schenk, Joshua E Reuss, Karin Choquette, et al.
Clinical Lung Cancer|December 12, 2025
Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLCAlexander I Spira, David Berz, Robert M Jotte, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2025
A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups"Matthew G Krebs, Byoung Chul Cho, Priya Kim, et al.
Advances in Therapy|May 29, 2025
Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended TherapyAlexander I Spira, Tao Ran, Iris Lin, et al.
ESMO Open|September 6, 2025
Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolismS A Piha-Paul, A W Tolcher, A L Vandross, et al.
Medical Oncology (Northwood, London, England)|April 27, 2017
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancerBryan Oronsky, Carolyn M Ray, Alexander I Spira, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2009
Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancerCraig Reynolds, David Barrera, Robert Jotte, et al.
The Journal of Experimental Medicine|January 1, 1996
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaquesA I Spira, P A Marx, B K Patterson, et al.
Pageof 10